The aim of this study was to identify the clinical drivers of improvement in patient-reported outcomes (PROs) in patients with PNH receiving the complement component 5 (C5) inhibitors eculizumab and ravulizumab. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.